The Muscular Dystrophy Association (MDA) announces the awarding of 15 new MDA grants totaling more than $4 million toward research focused on a variety of neuromuscular diseases.
This round of grant funding reinforces MDA’s unwavering commitment to the progress of neuromuscular disease research and builds on the more than $1 billion MDA has already invested in research to uncover new treatments and cures for NMDs since its inception. Some grants will go into effect this year, while others will be awarded in 2021, a media release from MDA explains.
“We continue to fund the most innovative research that will lead us to cures for a range of neuromuscular diseases. We have already seen our investment pay off with the first effective neuromuscular disease therapies, and these grantees are pushing the envelope even further in diseases once thought incurable.
“Although COVID led the cancellation of MDA’s spring review session, we are pleased to announce the funding of these projects, which were reviewed in 2019.”
— Sharon Hesterlee, PhD, executive vice president and chief research officer for Muscular Dystrophy Association
The newly funded projects will aim to advance research discoveries and new therapy development in multiple areas. The awarded grants will fund studies to further advance our understanding of genetic causes of and risk factors for NMDs, investigate new approaches to developing gene therapies and other innovative potential treatments, including stopping disease progression and improving genetic testing technologies, the release continues.
For a complete list of individual awards for this grant cycle, visit the Muscular Dystrophy Association.
[Source(s): Muscular Dystrophy Association, PR Newswire]